<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205465</url>
  </required_header>
  <id_info>
    <org_study_id>VX04-765-301</org_study_id>
    <nct_id>NCT00205465</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis
      treated for 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal laboratory values</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal ECGs and vital signs</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK/PD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion score after 28 days of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects meeting &quot;clear&quot; or &quot;almost clear&quot; criteria utilizing a static Physician's Global Assessment (sPGA)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects demonstrating ≥ 50% and ≥ 75% decrease from baseline in Psoriasis Area and Severity Index (PASI) to the end of 28 days of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PASI from baseline to the end of 28 days of treatment</measure>
  </secondary_outcome>
  <enrollment>64</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-765</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with chronic plaque psoriasis for at least 6 months

          -  Prior systemic therapy

        Exclusion Criteria:

          -  Current or prior history of illness precluding use of immunomodulatory therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Robert Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vertex Pharmaceuticals Incorporated</affiliation>
  </overall_official>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 3, 2007</last_update_submitted>
  <last_update_submitted_qc>December 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2007</last_update_posted>
  <responsible_party>
    <name_title>Robert Kauffman, M.D., Ph.D</name_title>
    <organization>Vertex Pharmaceuticals Incorporated</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

